The 13th Annual Personalized Medicine Conference will define the landscape, outlook and next steps for personalized medicine in science, business and policy.
November 14 - 16, 2017
Joseph B. Martin Conference Center
Harvard Medical School
Speakers for the 13th Annual Personalized Medicine Conference provide head shots and biographical descriptions on a rolling basis.
Amy Abernethy, M.D., Ph.D.
Chief Medical Officer
Chief Scientific Officer
Amy P. Abernethy, M.D., Ph.D., is the Chief Medical Officer and Chief Scientific Officer at Flatiron Health, a healthcare technology and services company focused on accelerating cancer research and improving patient care. She is a hematologist/oncologist and palliative medicine physician, and internationally-recognized cancer clinical researcher with more than 400 publications.
Dr. Abernethy is an appointee to the National Academy of Medicine’s (formerly the Institute of Medicine) National Cancer Policy Forum, on the Executive Board for the Personalized Medicine Coalition, and Past President of the American Academy of Hospice & Palliative Medicine. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. She is also on the Board of Directors of athenahealth, Inc. and was featured on TEDMED in 2013.
Steven D. Averbuch, M.D.
Head, Precision Medicine, R & D
Dr. Averbuch is the Head, Precision Medicine within the Translational Medicine Division of R&D at Bristol-Myers Squibb. In this role, Steve leads integrated biomarker and pharmacodiagnostic activities across the BMS R & D portfolio.
Dr. Averbuch joined Bristol-Myers Squibb in 2006 and he has led the Pharmacodiagnostics Center of Excellence since 2008. Other previous roles included: leading the strategy, business development agreements and execution of external clinical collaborations for the company’s immuno-oncology pipeline; executive sponsor and oversight for translational research activities for all late development and marketed oncology compounds; leader of corporate-wide strategic initiatives for Translational and Targeted Medicine; co-leader of the Oncology early strategy team and that included responsibility for the execution of Phase 2 Oncology programs.
Dr. Averbuch previously held positions at Merck Research Laboratories, AstraZeneca and Mount Sinai School of Medicine. He is currently on the Personalized Medicine Coalition Board of Directors, the Steering Committee of the National Biomarker Development Alliance and the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation.Dr. Averbuch is the 2014 recipient of the University of Illinois College of Medicine Distinguished Alumnus Award. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.
Scott Beck, M.B.A.
Center for Individualized Medicine
Scott Beck is an Administrator of the Mayo Clinic’s Center for Individualized Medicine, which he helped form in 2011, creating a vision and mission to discover, translate and apply new individualized medicine products and services that continually differentiate clinical practice for every life Mayo touches. In 2015, Scott also began providing clinical practice support for the Department of Clinical Genomics, and in 2017, he also began supporting research translation, test development and clinical integration for the Department of Laboratory Medicine and Pathology and Mayo Medical Laboratories.
Scott began his career at Mayo Clinic in 1992 in Mayo Medical Ventures, a for-profit diversification activity within Mayo Clinic. From 1998 to 2006, he worked as an Administrator in the Department of Research Services, helping to launch Mayo’s Molecular Medicine Program and Genomics Research Center. Scott also facilitated the start-up of the Minnesota Partnership for Biotechnology and Medical Genomics, a public-private initiative with the University of Minnesota and the Minnesota legislature in support of biomedical research. The Partnership has since received over $120 million in support from both state and private funding sources. From 2006 to 2011, Scott worked as an Administrator in Information Technology, where he helped initiate and implement data governance and data warehousing strategies for Mayo. Prior to joining Mayo Clinic, Scott worked as a staff consultant for Andersen Consulting.
Katrine Bosley is the Chief Executive Officer of Editas Medicine and has been part of the biotechnology industry for more than 25 years. Before joining Editas, Katrine was Entrepreneur-in-Residence at The Broad Institute, as well as CEO of Avila Therapeutics and Vice President of Business Development of Adnexus Therapeutics. Throughout her career, she worked to advance innovative products and technologies, including Tysabri (natalizumab), covalent drugs and genome editing. She has led and supported a wide range of transactions with an aggregate realized value of over $2 billion and total potential value exceeding $8 billion. Katrine is a graduate of Cornell University where she received a B.A. as a College Scholar.
Katrine has been recognized as one of the 100 Most Creative People in Business by Fast Company (2016), as one of 30 Global Game Changers by Forbes (2016), as Entrepreneur of the Year by the New England Venture Capital Association (2013), and as one of the Top Ten Women in Biotech by FierceBiotech (2010).
In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences and is a Board member of Galapagos NV, and of BIO – the Biotechnology Innovation Organization.
Timothy Cannon, M.D.
Inova Schar Cancer Institute Molecular Tumor Board
Inova Health System
Dr. Timothy Cannon is a medical oncologist and clinical director of the Inova Schar Institute Molecular Tumor Board (MTB). He specializes in gastrointestinal malignancies and is an assistant professor at Virginia Commonwealth University. He has been the moderator of the MTB since it began in March of 2016, which matches patients with targeted therapies based on molecular diagnostics. He is the site principal investigator for the Targeted Agent and Profiling Utilization Registry (TAPUR) study, as well as many other clinical trials in immunotherapy.
Dr. Cannon received his M.D. from Rutgers Medical School and completed his residency at George Washington University Medical Center Internal Medicine. He completed a fellowship in hematology/oncology at New York University, where he was the chief fellow.
Arthur L. Caplan, Ph.D.
Drs. William F. and Virginia Connolly Mitty Chair and Director
Division of Medical Ethics
New York University Langone Medical Center
Dr. Arthur L. Caplan is the Drs. William F and Virginia Connolly Mitty Chair and Professor, and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City.
Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Dr. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his Ph.D. from Columbia University.
He is currently the ethics advisor to the U.S. Department of Defenses’s Defense Advanced Research Projects Agency on synthetic biology, a member of the University of Pennsylvania’s External Advisory Committee for its Orphan Disease Center, a member of the Ethics and Ebola Working Group of the World Health Organization and an advisor to the National Institutes of Health on organ transplantation.
Dr. Caplan is the author or editor of thirty-five books and more than 725 papers in peer-reviewed journals. His most recent books are The Ethics of Sport, (Oxford University Press, 2016 with Brendan Parent) and Vaccination Ethics and Policy, (MIT Press, 2017 with Jason Schwartz).
George Church, Ph.D.
Professor of Genetics, Health Sciences, Technology, Harvard and MIT;
Director of HMS NHGRI-Center of Excellence in Genomic Science;
Director of the Personal Genome Project, Broad Institute & Wyss Harvard Institute of Biologically Inspired Engineering
Harvard Medical School
George Church is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT and Director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard.
George is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first commercial genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers.
Andrea Stern Ferris
Chairman of the Board
Andrea became involved with lung cancer advocacy following her mother’s death from the disease in 2008. After receiving a diagnosis of stage IV lung cancer in 2006, Andrea’s mother underwent numerous treatments and clinical trials at several major academic institutions to no avail. Together with her father, Andrea was her mother’s primary caregiver during this time. Determined to drive more money into lung cancer research, Andrea left the successful software company that she helped launch, to found Protect Your Lungs, an organization focused 100% on funding early detection research. In 2010, Andrea merged Protect Your Lungs with LUNGevity, a Chicago based organization, to form the nation’s leading lung cancer focused non-profit.
Andrea’s strong business background combined with her connections to the worlds of research and advocacy have enabled her to build the preeminent patient advocacy organization in the lung cancer space. LUNGevity funds translational research into both early detection and more effective treatments of lung cancer as well as a highly coveted Career Development Awards program. LUNGevity also fills unmet needs for people diagnosed with lung cancer by providing education, support and survivorship programs. Recognizing the need to build awareness and understanding about lung cancer, LUNGevity has built the largest grassroots network of events and advocates across the country.
Sandro Galea, M.D., Dr.P.H.
Dean, Robert A. Knox Professor
School of Public Health
Dr. Sandro Galea, a physician and an epidemiologist, is Dean and Robert A. Knox Professor at Boston University School of Public Health. He previously held academic and leadership positions at Columbia University, the University of Michigan and the New York Academy of Medicine. In his scholarship, Galea is centrally interested in the social production of health of urban populations, with a focus on the causes of brain disorders, particularly common mood-anxiety disorders and substance abuse.
Dr. Galea was named one of Time magazine’s epidemiology innovators, and has been listed by Thomson Reuters as one of the “World’s Most Influential Scientific Minds” for the social sciences. He is past president of the Society for Epidemiologic Research and an elected member of the National Academy of Medicine and the American Epidemiological Society. Galea has received several lifetime achievement awards for his research, including the Rema Lapouse Award from the American Public Health Association and the Robert S. Laufer, Ph.D., Memorial Award from the International Society for Traumatic Stress Studies. Galea holds a medical degree from the University of Toronto and graduate degrees from Harvard University and Columbia University. He also holds an honorary doctorate from the University of Glasgow.
Joydeep Goswami, Ph.D., M.B.A.
President, Clinical Next-Generation Sequencing, Oncology
Thermo Fisher Scientific
Joydeep Goswami has been President, Clinical Next Generation Sequencing and Oncology Division (CSD) since July 2016. CSD is focused on serving the targeted sequencing needs of customers in research and clinical applications, with an emphasis on oncology.
Prior to his current role, Dr. Goswami was the VP/GM of the Protein and Cell Analysis (PCA) business at Thermo Fisher, between April 2015 and July 2016. He joined Thermo Fisher as President of Asia Pacific and Japan, Life Sciences Solutions in 2014 through the acquisition of Life Technologies. Dr. Goswami has held various executive positions at Life Technologies, including President of Life Technologies Japan, Vice President and General Manager of Primary and Stem Cell Systems, and Vice President of Stem Cells and Regenerative Medicine. He joined Life Technologies (then Invitrogen) in 2003 as Director, Corporate Development, Global Head of Licensing.
Before joining Life Technologies, he worked at McKinsey & Company, serving clients in the pharmaceutical, medical products, chemical, and technology industries in the U.S., Europe, Asia and Latin America.
Joydeep has a Ph.D. and M.S. in Chemical Engineering from Massachusetts Institute of Technology, an M.B.A. from MIT Sloan School of Management. He holds a Bachelor of Technology in Chemical Engineering from Indian Institute of Technology.
Scott Gottlieb, M.D.
Dr. Scott Gottlieb was sworn in as the 23rd Commissioner of Food and Drugs on May 10, 2017. Dr. Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a senior advisor to the FDA Commissioner.
He also worked on implementation of the Medicare drug benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency’s coverage process, particularly as it related to new medical technologies.
In 2013 Dr. Gottlieb was appointed by the Senate to serve on the Federal Health Information Technology Policy Committee, which advises the Department of Health and Human Services on healthcare information technology.
Dr. Gottlieb was previously a Resident Fellow at the American Enterprise Institute, and a Clinical Assistant Professor at the New York University School of Medicine in Manhattan, where he also practiced medicine as a hospitalist physician.
He completed a residency in internal medicine at the Mount Sinai Medical Center in New York, New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.
Richard Hamermesh, M.B.A., D.B.A.
Co-Chair, Kraft Precision Medicine Accelerator
Professor of Management Practice, Retired
Harvard Business School
Richard Hamermesh is a Senior Fellow at the Harvard Business School where he was formerly the MBA Class of 1961 Professor of Management Practice. Currently, Richard is the faculty co-chair of the HBS/Kraft Precision Medicine Accelerator. Richard created and teaches the second-year MBA elective, Building Life Science Businesses. Previously, he was the Course Head for the required first year course, The Entrepreneurial Manager.
From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School.
Richard is also an active investor and entrepreneur, having participated as a principal, director, and investor in the founding and early stages of more than 20 organizations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review.
Richard is the author or co-author of five books, including New Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published more than 100 case studies and numerous, including his recent publications "What Precision Medicine Can Learn from the NFL" and "One Obstacle to Curing Cancer: Patient Data isn't Shared." Richard received his undergraduate degree from the University of California, and his M.B.A. and DBA from Harvard Business School.
Peter Hulick, M.D., M.M.Sc.
Medical Director, Center for Personalized Medicine
NorthShore University HealthSystem
Peter Hulick, M.D., M.M.Sc., is the Medical Director of the Center for Personalized Medicine and Medical Director for the Center for Medical Genetics at NorthShore University HealthSystem (NorthShore), which applies genetic analysis to prevention, diagnosis and treatment of inherited diseases and disorders. He joined NorthShore as an attending physician in medical genetics in 2008 and became Division Head of Medical Genetics in 2012.
Dr. Hulick also serves as a Clinical Assistant Professor in the Department of Human Genetics at the University of Chicago Pritzker School of Medicine. Previously, he served as an attending physician in medical genetics at Massachusetts General Hospital in Boston, Massachusetts. He has authored or co-authored more than 20 peer reviewed journal articles.
Dr. Hulick earned his medical degree from Jefferson Medical College in 2001. He completed a residency in internal medicine at St. Luke’s Hospital – Mayo Clinic, and completed a clinical fellowship in medical genetics at Harvard Medical School. He also earned a master’s degree in medical science from Harvard Medical School in 2007.